CD274 and neoplasm: Patients with an unfavorable prognosis due to PD-L1+ tumor cells and fewer TILs [10], especially with less infiltration of PD-L1+ immune cells, would be the next candidates for therapeutic targeting to prevent tumors escaping immune surveillance.